0001493152-23-029156.txt : 20230816 0001493152-23-029156.hdr.sgml : 20230816 20230816160532 ACCESSION NUMBER: 0001493152-23-029156 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230816 DATE AS OF CHANGE: 20230816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cocrystal Pharma, Inc. CENTRAL INDEX KEY: 0001412486 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 352528215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38418 FILM NUMBER: 231178227 BUSINESS ADDRESS: STREET 1: 19805 N. CREEK PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 BUSINESS PHONE: (786) 459-1831 MAIL ADDRESS: STREET 1: 19805 N. CREEK PARKWAY CITY: BOTHELL STATE: WA ZIP: 98011 FORMER COMPANY: FORMER CONFORMED NAME: BIOZONE PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20110304 FORMER COMPANY: FORMER CONFORMED NAME: International Surf Resorts, Inc. DATE OF NAME CHANGE: 20070917 8-K 1 form8-k.htm
0001412486 false 0001412486 2023-08-14 2023-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2023

 

Cocrystal Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38418   35-2528215

(State or other Jurisdiction

of Incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

19805 N. Creek Parkway

Bothell, WA

  98011
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (786) 459-1831

 

 

(Former name or former address, if changed since last report.):

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock   COCP   The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)

 

 

 

 
 

 

Item 2.02 Results of Operations and Financial Condition

 

On August 14, 2023, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit   Description
     
99.1   Press Release dated August 14, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Cocrystal Pharma, Inc.
     
Date: August 16, 2023 By: /s/ James Martin
  Name: James Martin
  Title: Chief Financial Officer and Co-Chief Executive Officer

 

 

EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

August 14, 2023

 

Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

 

On track to begin a Phase 2a trial in the second half of 2023 with CC-42344 for the treatment of pandemic and seasonal influenza A
Selected the novel protease inhibitor CDI-988 as development lead in the oral norovirus program
CDI-988, the first potential dual coronavirus-norovirus oral antiviral, was cleared by the Australian regulatory agency for evaluation in healthy volunteers

 

BOTHELL, Wash., Aug. 14, 2023 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) reports financial results for the three and six months ended June 30, 2023, and provides updates on its antiviral pipeline, upcoming milestones and business activities.

 

“This is an eventful time for Cocrystal with notable advancements in developing our pipeline of highly promising antivirals,” said Sam Lee, Ph.D., President and co-CEO of Cocrystal. “With our novel oral PB2 inhibitor CC-42344 for the treatment of pandemic and seasonal influenza A, we are building on the favorable data from our Phase 1 trial with the submission of an application for UK MHRA (Medicine and Healthcare Products Regulatory Agency) approval to begin a Phase 2a human challenge trial later this year.

 

“In our COVID-19 program, we received approval from the Australian regulatory agency in late May to begin a first-in-human trial with our novel, broad-spectrum oral protease inhibitor CDI-988. Earlier this month we announced the selection of CDI-988 as our lead oral norovirus candidate. This Phase I study is designed to access the safety, tolerability, and pharmacokinetics of CDI-988 for both our COVID-19 and our norovirus programs. We expect to report top-line data of CDI-988 Phase 1 study in 2024.”

 

“We have a number of significant near-term inflection points with our three leading antiviral programs including the commencement of multiple clinical trials,” said James Martin, CFO and co-CEO. “I’m pleased to report that under our cost-efficient business model, we believe our current cash position is sufficient to fund our planned operations for the next 12 months.”

 

Antiviral Product Pipeline Overview

 

We are developing therapeutics that inhibit the viral replication function of RNA viruses that cause acute and chronic diseases. Our drug discovery process focuses on the highly conserved regions of the viral enzymes and inhibitor-enzyme interactions at the atomic level. It differs from traditional, empirical medicinal chemistry approaches that often require iterative high-throughput compound screening and lengthy hit-to-lead processes. By designing and selecting antiviral drug candidates that interrupt the viral replication process and have specific binding characteristics, we seek to develop drugs that are effective against both the virus and mutants of the virus, and also have reduced off-target interactions that may cause undesirable clinical side effects.

 

 
 

 

Influenza Programs

 

Influenza is a severe respiratory illness caused by the influenza A or B virus that results in disease outbreaks mainly during the winter months. The global seasonal influenza market including diagnostics, treatments and vaccines is projected to reach up to $27.95 billion by 2029, according to Data Bridge Market Research.

 

Pandemic and Seasonal Influenza A

 

Our novel oral PB2 inhibitor CC-42344 has shown excellent antiviral activity against influenza A strains including pandemic and seasonal strains, as well as strains that are resistant to Tamiflu® and Xofluza®.
In March 2022 we initiated enrollment in a randomized, double-controlled, dose-escalating Phase 1 trial to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered CC-42344 in healthy adults.
In April 2022 we announced preliminary Phase 1 trial data demonstrating a favorable safety and PK profile in the first two cohorts in the single-ascending-dose portion of the study.
In July 2022 we reported PK results from the single-ascending-dose portion of the study that support once-daily dosing.
In December 2022 we reported favorable safety and tolerability results from the CC-42344 Phase 1 trial.
We entered into an agreement with a UK-based clinical research organization to conduct a Phase 2a human challenge study to evaluate safety, and viral and clinical measures of orally administered CC-42344 in influenza A-infected subjects.
We submitted an application to the United Kingdom Medicines and Healthcare Products Regulatory Agency to conduct the Phase 2a human challenge study and, pending clearance, we expect to initiate the study in the second half of 2023.
Preclinical development is underway with an inhaled formulation of CC-42344 as a potential treatment and prophylaxis for influenza A. We expect to complete active pharmaceutical ingredient (API) manufacturing in preparation for toxicity studies, and to begin the Phase 1 clinical trial in the first half of 2024.

 

Pandemic and Seasonal Influenza A/B Program

 

In January 2019 we entered into an Exclusive License and Research Collaboration Agreement with Merck Sharp & Dohme Corp. (Merck) to discover and develop certain proprietary influenza antiviral agents that are effective against both influenza A and B strains. This agreement includes milestone payments of up to $156 million plus royalties on sales of products discovered under the agreement.
In January 2021 we announced completion of all research obligations under the agreement, making Merck solely responsible for further preclinical and clinical development of these compounds.
In early 2023 Merck notified us of its intent to continue development of the proprietary compounds discovered under this agreement and of their filing on behalf of both companies of multiple U.S. and international patent applications associated with these compounds. Merck continues to be responsible for managing the patents.

 

 
 

 

COVID-19 and Other Coronavirus Programs

 

By targeting viral replication enzymes and protease, we believe it is possible to develop effective treatments for all diseases caused by coronaviruses including COVID-19, Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). Our main SARS-CoV-2 protease inhibitors showed potent in vitro pan-viral activity against common human coronaviruses, rhinoviruses and respiratory enteroviruses that cause the common cold, as well as against noroviruses that can cause symptoms of acute gastroenteritis.

 

Oral Protease Inhibitor CDI-988

 

In August 2023 we announced the selection of CDI-988 as our lead candidate for development as a potential oral treatment for SARS-CoV-2. Designed and developed using our proprietary structure-based drug discovery platform technology, CDI-988 targets a highly conserved region in the active site of SARS-CoV-2 3CL (main) protease required for viral RNA replication.
CDI-988 exhibited superior in vitro potency against SARS-CoV-2 with activity maintained against variants of concern, and demonstrated a safety profile and PK properties that are supportive of once-daily dosing.
In May 2023 we announced approval of our application to the Australian regulatory agency for a planned randomized, double-blind, placebo-controlled Phase 1 trial in healthy volunteers.
We believe the FDA’s guidance for further development of our antiviral candidate CDI-45205 (described below) assists us in designing a subsequent Phase 2 trial for CDI-988.

 

Intranasal/Pulmonary Protease Inhibitor CDI-45205

 

CDI-45205 is our novel SARS-CoV-2 3CL (main) protease inhibitor and was among the broad-spectrum viral protease inhibitors we obtained from Kansas State University Research Foundation (KSURF) under an exclusive license agreement announced in April 2020. We believe the protease inhibitors obtained from KSURF have the ability to inhibit the inactive SARS-CoV-2 polymerase replication enzymes into an active form.
CDI-45205 and several analogs showed potent in vitro activity against the main SARS-CoV-2 variants, surpassing the activity observed with the original Wuhan strain of the virus.
CDI-45205 demonstrated good bioavailability in mouse and rat PK studies via intraperitoneal injection, and no cytotoxicity against a variety of human cell lines. CDI-45205 also demonstrated a strong synergistic effect with the FDA-approved COVID-19 medicine remdesivir.
In January 2022 we received guidance from the FDA regarding further preclinical and clinical development of CDI-45205, which provides a clearer pathway for future development.
An IND-enabling study is ongoing with CDI-45205.

 

Replication Inhibitors

 

We are using our proprietary structure-based drug discovery platform technology to discover replication inhibitors for orally administered therapeutic and prophylactic treatments for SARS-CoV-2. Replication inhibitors hold potential to work with protease inhibitors in combination therapy regimens.

 

Norovirus Program

 

In August 2023 we announced our selection of the novel broad-spectrum 3CL protease inhibitor CDI-988 as our lead potential oral treatment for norovirus. CDI-988 is approved for evaluation in a first-in-human trial in healthy volunteers in Australia, and that trial is expected to serve as the Phase 1 trial for both our norovirus and our coronavirus programs.
With no approved treatments or vaccines, norovirus represents a significant unmet medical need. It is a highly contagious infection and is the most common cause of acute gastroenteritis, accounting for nearly one in five cases. According to the Centers for Disease Control and Prevention (CDC), an estimated 685 million cases and an estimated 200,000 deaths are attributed to norovirus each year worldwide, with an estimated societal cost of $60 billion.

 

 
 

 

Hepatitis C Program

 

We are seeking a partner to advance development of CC-31244 following the successful completion of a Phase 2a trial. This compound has shown favorable safety and preliminary efficacy in a triple-regimen Phase 2a trial in combination with Epclusa (sofosbuvir/velpatasvir) for the ultra-short duration treatment of individuals infected with the hepatitis C virus (HCV).
HCV is a viral infection of the liver that causes both acute and chronic infection. The World Health Organization estimated that 58 million people worldwide had chronic HCV infection in 2019.

 

Corporate Updates

 

In April we announced the appointment of Fred Hassan to our Board of Directors. Mr. Hassan’s distinguished 40-year career includes serving in senior executive and director positions at global pharmaceutical companies and leading investment firms. He currently is Chairman of the investment firm Caret Group and a Director of Warburg Pincus LLC, a global private equity firm.
In April we completed a $4.0 million private placement offering of common stock with Mr. Hassan and Phillip Frost, M.D., a Company co-founder and director, who currently is Chairman and CEO of OPKO Health.

 

Second Quarter Financial Results

 

Research and development (R&D) expenses for the second quarter of 2023 were $2.8 million, compared with $2.4 million for the second quarter of 2022. The increase was primarily due to preparations for a Phase 2a clinical trial with CC-42344 for pandemic and seasonal influenza A, and preparations for advancing CDI-988’s COVID-19 and norovirus programs toward a Phase 1 clinical trial.

 

General and administrative (G&A) expenses for the second quarter of 2023 were $1.5 million, compared with $1.4 million for the second quarter of 2022, with the increase primarily due to professional fees and general corporate cost increases.

 

The net loss for the second quarter of 2023 was $4.2 million, or $0.41 per share, compared with the net loss for the second quarter of 2022 of $24.4 million, or $3.00 per share. The second quarter of 2022 included a legal settlement of $1.6 million, which was returned to the Company in the third quarter of 2023 following a successful appeal of the trial court’s summary judgment ruling. In the second quarter of 2022, the Company also recorded a non-cash goodwill impairment of $19.1 million.

 

Six Month Financial Results

 

R&D expenses for the six months ended June 30, 2023 were $6.7 million, compared with $5.2 million for the first six months of 2022. G&A expenses for the six months ended June 30, 2023 and 2022 were unchanged at $2.7 million.

 

During the first six months of 2022, the Company recorded a $19.1 million non-cash goodwill impairment. There was no comparable impairment charge during the first six months of 2023.

 

The net loss for the six months ended June 30, 2023 was $9.4 million, or $1.03 per share. The net loss for the six months ended June 30, 2022 was $28.6 million, or $3.48 per share, and reflected the litigation expense and non-cash impairment charge described above.

 

Cocrystal reported unrestricted cash as of June 30, 2023 of $32.4 million, compared with $37.1 million as of December 31, 2022. Net cash used in operating activities for the first six months of 2023 was $8.7 million. The Company had working capital of $34.1 million and 10.2 million common shares outstanding as of June 30, 2023. During the second quarter of 2023, the Company raised $4.0 million in a private placement offering of common stock that was priced “at-the-market” under Nasdaq Listing Rules.

 

 
 

 

About Cocrystal Pharma, Inc.

 

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding our plans for the future development of preclinical and clinical drug candidates, our expectations regarding future characteristics of the product candidates we develop, the expected time of achieving certain value-driving milestones in our programs, including, preparation, commencement and advancement of clinical studies for certain product candidates in 2023 and beyond, the viability and efficacy of potential treatments for coronavirus and other diseases, expectations for the markets for certain therapeutics, our ability to execute our clinical and regulatory goals and deploy regulatory guidance towards future studies, the expected sufficiency of our cash balance to advance our programs and fund our planned operations, and our liquidity. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from the risks arising from interest rate increases in response to inflation, uncertainty in the financial markets, the possibility of a recession and the Ukraine war on our Company, our collaboration partners, and on the U.S., U.K., Australia and global economies, including manufacturing and research delays arising from raw materials and labor shortages, supply chain disruptions and other business interruptions including any adverse impacts on our ability to obtain raw materials and test animals as well as similar problems with our vendors and our current and any future CROs and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed with, clinical studies, our reliance on Merck for further development in the influenza A/B program under the license and collaboration agreement, our and our collaboration partners’ technology and software performing as expected, financial difficulties experienced by certain partners, the results of any current and future preclinical and clinical trials, general risks arising from clinical trials, receipt of regulatory approvals, regulatory changes, development of effective treatments and/or vaccines by competitors, including as part of the programs financed by the U.S. government, potential mutations in a virus we are targeting which may result in variants that are resistant to a product candidate we develop, and the outcome of the ongoing litigation with the insurance company. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2022. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

 

Investor Contact:

LHA Investor Relations

Jody Cain

310-691-7100

jcain@lhai.com

 

Media Contact:

JQA Partners

Jules Abraham

917-885-7378

Jabraham@jqapartners.com

 

Financial Tables to follow

 

 
 

 

COCRYSTAL PHARMA, INC.

 

CONSOLIDATED BALANCE SHEETS
(in thousands)

   June 30, 2023   December 31, 2022 
    (unaudited)      
Assets          
Current assets:          
Cash  $32,419   $37,144 
Restricted cash   75    75 
Tax credit receivable   1,207    716 
Prepaid expenses and other current assets   1,200    2,243 
Total current assets   34,901    40,178 
Property and equipment, net   305    342 
Deposits   46    46 
Operating lease right-of-use assets, net (including $72 and $99 respectively, to related party)   167    274 
Total assets  $35,419   $40,840 
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable and accrued expenses  $1,421   $976 
Current maturities of finance lease liabilities   -    7 
Current maturities of operating lease liabilities (including $62 and $59 respectively, to related party)   166    233 
Total current liabilities   1,587    1,216 
Long-term liabilities:          
           
Operating lease liabilities (including $10 and $42 respectively, to related party)   10    57 
           
Total liabilities   1,597    1,273 
           
Commitments and contingencies          
           
Stockholders’ equity:          
Common stock, $0.001 par value; 150,000 shares authorized as of June 30, 2023, and December 31, 2022; 10,174 and 8,143 shares issued and outstanding as of June 30, 2023 and December 31, 2022   10    8 
Additional paid-in capital   341,957    337,489 
Accumulated deficit   (308,145)   (297,930)
Total stockholders’ equity   33,822    39,567 
Total liabilities and stockholders’ equity  $35,419   $40,840 

 

 
 

 

COCRYSTAL PHARMA, INC.

 

CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in thousands, except per share data)

 

   Three months ended
June 30,
   Six months ended
June 30,
 
   2023   2022   2023   2022 
Operating expenses:                    
Research and development   3,661    2,361    7,568    5,233 
General and administrative   1,538    1,375    2,742    2,708 
Legal settlement   -    1,600    -    1,600 
Impairments   -    19,092    -    19,092 
Total operating expenses   5,199    24,428    10,310    28,633 
                     
Loss from operations   (5,199)   (24,428)   (10,310)   (28,633)
Other income (expense):                    
Interest income (expense), net   140    -    140    (1)
Foreign exchange loss   33    (1)   (45)   (14)
Change in fair value of derivative liabilities   -    1    -    12 
Total other expense, net   173    -    95    (3)
Net loss  $(5,026)  $(24,428)   (10,215)   (28,636)
Net loss per common share, basic and diluted  $(0.50)  $(3.00)   (1.12)   (3.48)
Weighted average number of common shares outstanding, basic and diluted   10,065    8,143    9,109    8,143 

 

# # #

 

 

 

GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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cocp-20230814.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 cocp-20230814_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 cocp-20230814_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 14, 2023
Entity File Number 001-38418
Entity Registrant Name Cocrystal Pharma, Inc.
Entity Central Index Key 0001412486
Entity Tax Identification Number 35-2528215
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 19805 N. Creek Parkway
Entity Address, City or Town Bothell
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98011
City Area Code (786)
Local Phone Number 459-1831
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol COCP
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001412486 2023-08-14 2023-08-14 iso4217:USD shares iso4217:USD shares 0001412486 false 8-K 2023-08-14 Cocrystal Pharma, Inc. DE 001-38418 35-2528215 19805 N. Creek Parkway Bothell WA 98011 (786) 459-1831 false false false false false Common Stock COCP NASDAQ EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " 4@0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " "O@!!7)!Z; MHJT #X 0 &@ @ &H$0 >&PO7W)E;',O=V]R:V)O;VLN M>&UL+G)E;'-02P$"% ,4 " "O@!!799!YDAD! #/ P $P M @ &-$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) #X" #7 %$P ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://cocrystalpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm cocp-20230814.xsd cocp-20230814_lab.xml cocp-20230814_pre.xml ex99-1.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "cocp-20230814_lab.xml" ] }, "presentationLink": { "local": [ "cocp-20230814_pre.xml" ] }, "schema": { "local": [ "cocp-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "COCP", "nsuri": "http://cocrystalpharma.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://cocrystalpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://cocrystalpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-029156-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-029156-xbrl.zip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